Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Ending Cash Position : $3,089 Mil (As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Chugai Pharmaceutical Co Ending Cash Position?

Chugai Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2024 was $3,089 Mil.

Chugai Pharmaceutical Co's quarterly Ending Cash Position increased from Sep. 2023 ($2,241 Mil) to Dec. 2023 ($3,186 Mil) but then declined from Dec. 2023 ($3,186 Mil) to Mar. 2024 ($3,089 Mil).

Chugai Pharmaceutical Co's annual Ending Cash Position declined from Dec. 2021 ($2,352 Mil) to Dec. 2022 ($1,647 Mil) but then increased from Dec. 2022 ($1,647 Mil) to Dec. 2023 ($3,186 Mil).

Chugai Pharmaceutical Co Ending Cash Position Historical Data

The historical data trend for Chugai Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Ending Cash Position Chart

Chugai Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

1,869.29

2,045.69

2,352.16

1,646.74

3,185.65

Chugai Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															1,853.05	2,582.21	2,241.14	3,185.65	3,089.49

Chugai Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Chugai Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1543.032	+	1642.613
	=	3,186

Chugai Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	3061.536	+	27.954
	=	3,089

Chugai Pharmaceutical Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCY) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

CHGCF:USA 4519:Japan CUP:Germany

Address

1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324

Website

http://www.chugai-pharm.co.jp

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines

From GuruFocus

Jean Hynes Adds to Chugai Pharmaceutical Stake

By Kyle Ferguson Kyle Ferguson • 08-22-2016

Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain

By PRNewswire PRNewswire • 03-02-2023

T. Rowe Price Japan Fund Comments on Chugai Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood • 06-19-2020

T. Rowe Price Japan Fund Makes 4 New Buys in 3rd Quarter

By David Goodloe David Goodloe • 10-19-2016

Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology

By PRNewswire PRNewswire • 07-22-2020

Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology

By PRNewswire PRNewswire • 07-22-2020